John R Hurst

List of Publications by Year in Descending Order

Source: https://exaly.com/author-pdf/5863575/john-r-hurst-publications-by-year.pdf

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

10,384 48 203 100 h-index citations g-index papers 6.35 256 13,295 7.5 L-index avg, IF ext. papers ext. citations

#	Paper	IF	Citations
203	Predictive Factors for and Complications of Bronchiectasis in Common Variable Immunodeficiency Disorders <i>Journal of Clinical Immunology</i> , 2022 , 1	5.7	O
202	Development, deployment and evaluation of digitally enabled, remote, supported rehabilitation for people with long COVID-19 (Living With COVID-19 Recovery): protocol for a mixed-methods study <i>BMJ Open</i> , 2022 , 12, e057408	3	3
201	Discriminative Accuracy of Chronic Obstructive Pulmonary Disease Screening Instruments in 3 Lowand Middle-Income Country Settings <i>JAMA - Journal of the American Medical Association</i> , 2022 , 327, 151-160	27.4	5
200	Development of a core outcome set for multimorbidity trials in low/middle-income countries (COSMOS): study protocol <i>BMJ Open</i> , 2022 , 12, e051810	3	O
199	"NEWS2" as an Objective Assessment of Hospitalised COPD Exacerbation Severity <i>International Journal of COPD</i> , 2022 , 17, 763-772	3	O
198	Nasal and systemic inflammation in Chronic Obstructive Pulmonary Disease (COPD) <i>Respiratory Medicine</i> , 2022 , 106774	4.6	3
197	Cardiovascular outcomes in patients with COPD-OSA overlap syndrome: A systematic review and meta-analysis <i>Sleep Medicine Reviews</i> , 2022 , 63, 101627	10.2	O
196	Quality Standard Position Statements for Health System Policy Changes in Diagnosis and Management of COPD: A Global Perspective <i>Advances in Therapy</i> , 2022 , 39, 2302-2322	4.1	0
195	The Extremely Preterm Young Adult (State of the Art. Seminars in Fetal and Neonatal Medicine, 2022, 101365	3.7	O
194	Upper airway symptoms and Small Airways Disease in Chronic Obstructive Pulmonary Disease, COPD <i>Respiratory Medicine</i> , 2021 , 191, 106710	4.6	0
193	COVID-19 and 'basal' exacerbation frequency in COPD. <i>Thorax</i> , 2021 , 76, 432-433	7.3	3
192	Application of oxygen saturation variability analysis for the detection of exacerbation in individuals with COPD: A proof-of-concept study. <i>Physiological Reports</i> , 2021 , 9, e15132	2.6	2
191	Pulmonary rehabilitation for COPD: A narrative review and call for further implementation in Saudi Arabia. <i>Annals of Thoracic Medicine</i> , 2021 , 16, 299-305	2.2	3
190	Research priorities to address the global burden of chronic obstructive pulmonary disease (COPD) in the next decade. <i>Journal of Global Health</i> , 2021 , 11, 15003	4.3	3
189	Predictors of 30- and 90-Day COPD Exacerbation Readmission: A Prospective Cohort Study. <i>International Journal of COPD</i> , 2021 , 16, 2769-2781	3	1
188	Acceptability of hygiene, face covering and social distancing interventions to prevent exacerbations in people living with airways diseases. <i>Thorax</i> , 2021 ,	7.3	1
187	Physical, cognitive, and mental health impacts of COVID-19 after hospitalisation (PHOSP-COVID): a UK multicentre, prospective cohort study. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 1275-1287	35.1	58

(2021-2021)

186	Overcoming Therapeutic Inertia to Reduce the Risk of COPD Exacerbations: Four Action Points for Healthcare Professionals. <i>International Journal of COPD</i> , 2021 , 16, 3009-3016	3	1
185	Improving lung health in low-income and middle-income countries: from challenges to solutions. <i>Lancet, The</i> , 2021 , 397, 928-940	40	57
184	Remote Assessment of Lung Disease and Impact on Physical and Mental Health (RALPMH): Protocol for a Prospective Observational Study. <i>JMIR Research Protocols</i> , 2021 , 10, e28873	2	О
183	The high mental health burden of "Long COVID" and its association with on-going physical and respiratory symptoms in all adults discharged from hospital. <i>European Respiratory Journal</i> , 2021 , 57,	13.6	20
182	Treatment Strategies for GLILD in Common Variable Immunodeficiency: A Systematic Review. <i>Frontiers in Immunology</i> , 2021 , 12, 606099	8.4	3
181	A Systematic Literature Review of the Humanistic Burden of COPD. <i>International Journal of COPD</i> , 2021 , 16, 1303-1314	3	2
180	Upper airway symptoms associate with the eosinophilic phenotype of COPD. <i>ERJ Open Research</i> , 2021 , 7,	3.5	4
179	Size at birth, growth trajectory in early life, and cardiovascular and metabolic risks in early adulthood: EPICure study. <i>Archives of Disease in Childhood: Fetal and Neonatal Edition</i> , 2021 , 106, 149-1.	5 § ·7	7
178	Gaps in COPD Guidelines of Low- and Middle-Income Countries: A Systematic Scoping Review. <i>Chest</i> , 2021 , 159, 575-584	5.3	15
177	A Patient Charter for Chronic Obstructive Pulmonary Disease. <i>Advances in Therapy</i> , 2021 , 38, 11-23	4.1	5
176	'Long-COVID': a cross-sectional study of persisting symptoms, biomarker and imaging abnormalities following hospitalisation for COVID-19. <i>Thorax</i> , 2021 , 76, 396-398	7.3	270
175	Specialty COPD care during COVID-19: patient and clinician perspectives on remote delivery. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	10
174	Development and Validity Assessment of a Chronic Obstructive Pulmonary Disease Knowledge Questionnaire in Low- and Middle-Income Countries. <i>Annals of the American Thoracic Society</i> , 2021 , 18, 1298-1305	4.7	
173	Hepatobiliary phenotypes of adults with alpha-1 antitrypsin deficiency. <i>Gut</i> , 2021 ,	19.2	5
172	Effectiveness of low-dose theophylline for the management of biomass-associated COPD (LODOT-BCOPD): study protocol for a randomized controlled trial. <i>Trials</i> , 2021 , 22, 213	2.8	0
171	Operational Modeling with Health Economics to Support Decision Making for COPD Patients. Health Services Research, 2021 , 56, 1271-1280	3.4	2
170	Does pay-for-performance improve patient outcomes in acute exacerbation of COPD admissions?. <i>Thorax</i> , 2021 ,	7.3	1
169	Challenges in the Implementation of Chronic Obstructive Pulmonary Disease Guidelines in Lowand Middle-Income Countries: An Official American Thoracic Society Workshop Report. <i>Annals of the American Thoracic Society</i> 2021 , 18, 1269-1277	4.7	5

168	The long-term sequelae of COVID-19: an international consensus on research priorities for patients with pre-existing and new-onset airways disease. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 1467-1478	35.1	24
167	Addressing a system failure to diagnose COPD and asthma. <i>Lancet Respiratory Medicine,the</i> , 2021 , 9, 814-816	35.1	
166	Reduction in hospitalised COPD exacerbations during COVID-19: A systematic review and meta-analysis. <i>PLoS ONE</i> , 2021 , 16, e0255659	3.7	18
165	CONQUEST Quality Standards: For the Collaboration on Quality Improvement Initiative for Achieving Excellence in Standards of COPD Care. <i>International Journal of COPD</i> , 2021 , 16, 2301-2322	3	2
164	Research priorities for exacerbations of COPD. Lancet Respiratory Medicine, the, 2021, 9, 824-826	35.1	10
163	ROSE: radiology, obstruction, symptoms and exposure - a Delphi consensus definition of the association of COPD and bronchiectasis by the EMBARC Airways Working Group. <i>ERJ Open Research</i> , 2021 , 7,	3.5	3
162	An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary Disease Exacerbations: The Rome Proposal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2021 , 204, 1251-1258	10.2	10
161	Strategies for the prevention, diagnosis and treatment of COPD in low- and middle- income countries: the importance of primary care. <i>Expert Review of Respiratory Medicine</i> , 2021 , 15, 1563-1577	3.8	1
160	A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease in Low- and Middle-Income Country Settings. <i>International Journal of COPD</i> , 2020 , 15, 2769-2777	3	5
159	Correction to: We cand carry the weight of the whole world Illness experiences among Peruvian older adults with symptoms of depression and anxiety. <i>International Journal of Mental Health Systems</i> , 2020 , 14,	3.6	78
158	Risk factors and associated outcomes of hospital readmission in COPD: A systematic review. <i>Respiratory Medicine</i> , 2020 , 173, 105988	4.6	13
157	COPD exacerbation phenotypes in a real-world five year hospitalisation cohort. <i>Respiratory Medicine</i> , 2020 , 167, 105979	4.6	5
156	Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. <i>PLoS ONE</i> , 2020 , 15, e0233147	3.7	386
155	The effect of HIV status on the frequency and severity of acute respiratory illness. <i>PLoS ONE</i> , 2020 , 15, e0232977	3.7	2
154	Risk factors for all-cause hospital readmission following exacerbation of COPD: a systematic review and meta-analysis. <i>European Respiratory Review</i> , 2020 , 29,	9.8	37
153	Adequacy of Therapy for People with Both COPD and Heart Failure in the UK: Historical Cohort Study. <i>Journal of Pragmatic and Observational Research</i> , 2020 , 11, 55-66	7.4	2
152	Efficacy and Safety of LAMA/LABA Fixed-Dose Combination Therapies in Chronic Obstructive Pulmonary Disease: A Systematic Review of Direct and Indirect Treatment Comparisons. <i>International Journal of COPD</i> , 2020 , 15, 1529-1543	3	2
151	Relationship of CT densitometry to lung physiological parameters and health status in alpha-1 antitrypsin deficiency: initial report of a centralised database of the NIHR rare diseases translational research collaborative. <i>BMJ Open</i> , 2020 , 10, e036045	3	2

(2020-2020)

150	Nutritional supplementation during pulmonary rehabilitation in COPD: A systematic review. <i>Chronic Respiratory Disease</i> , 2020 , 17, 1479973120904953	3	7
149	Understanding the impact of chronic obstructive pulmonary disease exacerbations on patient health and quality of life. <i>European Journal of Internal Medicine</i> , 2020 , 73, 1-6	3.9	18
148	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. <i>Medicine</i> , 2020 , 48, 328-332	0.6	
147	Non-invasive testing for liver pathology in alpha-1 antitrypsin deficiency. <i>BMJ Open Respiratory Research</i> , 2020 , 7,	5.6	1
146	Once Daily Versus Overnight and Symptom Versus Physiological Monitoring to Detect Exacerbations of Chronic Obstructive Pulmonary Disease: Pilot Randomized Controlled Trial. <i>JMIR MHealth and UHealth</i> , 2020 , 8, e17597	5.5	5
145	Multimorbidity: Not Just for the West. <i>Global Heart</i> , 2020 , 15, 45	2.9	3
144	Global Burden of COPD 2020 , 1-20		2
143	COPD Exacerbations: A Patient and Physician's Perspective. <i>Advances in Therapy</i> , 2020 , 37, 10-16	4.1	3
142	Disease Progression Modeling in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 201, 294-302	10.2	20
141	National clinical audit for hospitalised exacerbations of COPD. ERJ Open Research, 2020, 6,	3.5	5
140	National clinical audit for hospitalised exacerbations of COPD. <i>ERJ Open Research</i> , 2020 , 6, Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333	3.5	5
, i	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. Frontiers in Immunology,		
140	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333 British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19	8.4	5
140	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333 British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. <i>BMJ Open</i> , 2020 , 10, e040213 A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination	8.4	5
140 139 138	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333 British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. <i>BMJ Open</i> , 2020 , 10, e040213 A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. <i>International Journal of COPD</i> , 2020 , 15, 3093-3103 Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review.	3 3	5
140 139 138	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333 British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. <i>BMJ Open</i> , 2020 , 10, e040213 A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. <i>International Journal of COPD</i> , 2020 , 15, 3093-3103 Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>International Journal of COPD</i> , 2020 , 15, 1751-1787 Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria	8.4 3 3	5 13 3
140 139 138 137	Managing Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders: e-GLILDnet International Clinicians Survey. <i>Frontiers in Immunology</i> , 2020 , 11, 606333 British Thoracic Society survey of rehabilitation to support recovery of the post-COVID-19 population. <i>BMJ Open</i> , 2020 , 10, e040213 A Comparison of the Real-Life Clinical Effectiveness of the Leading Licensed ICS/LABA Combination Inhalers in the Treatment for COPD. <i>International Journal of COPD</i> , 2020 , 15, 3093-3103 Thoracic Imaging at Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review. <i>International Journal of COPD</i> , 2020 , 15, 1751-1787 Enrichment of the airway microbiome in people living with HIV with potential pathogenic bacteria despite antiretroviral therapy. <i>EClinical Medicine</i> , 2020 , 24, 100427 Illness representations of chronic obstructive pulmonary disease (COPD) to inform health education strategies and research design-learning from rural Uganda. <i>Health Education Research</i> ,	8.4 3 3 11.3	51333

132	Caring for patients with COPD and COVID-19: a viewpoint to spark discussion. <i>Thorax</i> , 2020 , 75, 1035-10	D 3 3	11
131	Respiratory and Cardiovascular Outcomes in Survivors of Extremely Preterm Birth at 19 Years. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2020 , 202, 422-432	10.2	30
130	The effect of HIV status on the frequency and severity of acute respiratory illness 2020 , 15, e0232977		
129	The effect of HIV status on the frequency and severity of acute respiratory illness 2020 , 15, e0232977		
128	The effect of HIV status on the frequency and severity of acute respiratory illness 2020 , 15, e0232977		
127	The effect of HIV status on the frequency and severity of acute respiratory illness 2020 , 15, e0232977		
126	Global use, utility, and methods of tele-health in COPD: a health care provider survey. <i>International Journal of COPD</i> , 2019 , 14, 1713-1719	3	13
125	Outcome measures in a combined exercise rehabilitation programme for adults with COPD and chronic heart failure: A preliminary stakeholder consensus event. <i>Chronic Respiratory Disease</i> , 2019 , 16, 1479973119867952	3	3
124	Use, utility and methods of telehealth for patients with COPD in England and Wales: a healthcare provider survey. <i>BMJ Open Respiratory Research</i> , 2019 , 6, e000345	5.6	12
123	What is a COPD-Like Spirometry Test Result in Resource Constrained Settings?. <i>COPD: Journal of Chronic Obstructive Pulmonary Disease</i> , 2019 , 16, 213-214	2	1
122	Pulmonary rehabilitation, physical activity and aortic stiffness in COPD. <i>Respiratory Research</i> , 2019 , 20, 166	7.3	4
121	Building toolkits for COPD exacerbations: lessons from the past and present. <i>Thorax</i> , 2019 , 74, 898-905	7.3	17
120	Urban-Rural Disparities in Chronic Obstructive Pulmonary Disease Management and Access in Uganda. <i>Chronic Obstructive Pulmonary Diseases (Miami, Fla)</i> , 2019 , 6, 17-28	2.7	10
119	Modelling Airway Geometry as Stock Market Data Using Bayesian Changepoint Detection. <i>Lecture Notes in Computer Science</i> , 2019 , 345-354	0.9	
118	COPD and emphysema 2019 , 324-331		
117	Reproducibility of an airway tapering measurement in computed tomography with application to bronchiectasis. <i>Journal of Medical Imaging</i> , 2019 , 6, 034003	2.6	O
116	The National COPD Audit - what you need to know. Clinical Medicine, 2019,	1.9	1
115	British Thoracic Society Guideline for bronchiectasis in adults. <i>Thorax</i> , 2019 , 74, 1-69	7-3	132

114	Imaging of Bronchial Pathology in Antibody Deficiency: Data from the European Chest CT Group. Journal of Clinical Immunology, 2019 , 39, 45-54	5.7	17
113	Airway microbiome in adult survivors of extremely preterm birth: the EPICure study. <i>European Respiratory Journal</i> , 2019 , 53,	13.6	11
112	Reply to Lan and Shi: Different Background, Short Duration, and Inappropriate Participants May Harm Your Conclusion. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2019 , 199, 390-392	10.2	1
111	COPD exacerbations: transforming outcomes through research. <i>Lancet Respiratory Medicine,the</i> , 2018 , 6, 172-174	35.1	3
110	Pulmonary rehabilitation for patients with COPD during and after an exacerbation-related hospitalisation: back to the future?. European Respiratory Journal, 2018, 51,	13.6	2
109	Respiratory Infections and Antibiotic Usage in Common Variable Immunodeficiency. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2018 , 6, 159-168.e3	5.4	31
108	The overlap between bronchiectasis and chronic airway diseases: state of the art and future directions. <i>European Respiratory Journal</i> , 2018 , 52,	13.6	70
107	Consolidation and Exacerbation of COPD. Medical Sciences (Basel, Switzerland), 2018, 6,	3.3	4
106	Tapering analysis of airways with bronchiectasis 2018,		4
105	Gastroesophageal Reflux Disease (GERD) and COPD 2018 , 165-174		1
104	Validation of the Saint George's Respiratory Questionnaire in Uganda. <i>BMJ Open Respiratory Research</i> , 2018 , 5, e000276	5.6	3
	nescaran, 2010, St cooset o	J.0	
103	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018 , 6, e1270-e1271	13.6	24
103	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global</i>		24 8 ₇
	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018 , 6, e1270-e1271	13.6	
102	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018 , 6, e1270-e1271 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. <i>Trials</i> , 2018 ,	13.6 9.8	87
102	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018 , 6, e1270-e1271 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. <i>Trials</i> , 2018 , 19, 571 Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. <i>International Journal</i>	13.6 9.8 2.8	87
102	Global Alliance for Chronic Disease researchers' statement on multimorbidity. <i>The Lancet Global Health</i> , 2018 , 6, e1270-e1271 Cardiovascular disease and COPD: dangerous liaisons?. <i>European Respiratory Review</i> , 2018 , 27, Effectiveness-implementation of COPD case finding and self-management action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. <i>Trials</i> , 2018 , 19, 571 Factors influencing treatment escalation from long-acting muscarinic antagonist monotherapy to triple therapy in patients with COPD: a retrospective THIN-database analysis. <i>International Journal of COPD</i> , 2018 , 13, 781-792 Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical Trial.	13.6 9.8 2.8 3	87 17 15

96	The heterogeneity of systemic inflammation in bronchiectasis. <i>Respiratory Medicine</i> , 2017 , 127, 33-39	4.6	42
95	Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. <i>JAMA - Journal of the American Medical Association</i> , 2017 , 317, 2177-2186	27.4	254
94	British Lung Foundation/United Kingdom Primary Immunodeficiency Network Consensus Statement on the Definition, Diagnosis, and Management of Granulomatous-Lymphocytic Interstitial Lung Disease in Common Variable Immunodeficiency Disorders. <i>Journal of Allergy and</i>	5.4	86
93	Clinical Immunology: in Practice, 2017, 5, 938-945 Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. European Respiratory Journal, 2017, 49,	13.6	256
92	How Do Dual Long-Acting Bronchodilators Prevent Exacerbations of Chronic Obstructive Pulmonary Disease?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 139-149	10.2	54
91	Manifold Learning of COPD. <i>Lecture Notes in Computer Science</i> , 2017 , 10435, 46-54	0.9	1
90	Pulmonary rehabilitation and cardiovascular risk in COPD: a systematic review. <i>COPD Research and Practice</i> , 2017 , 3,		4
89	Susceptibility to exacerbation in COPD. Lancet Respiratory Medicine, the, 2017 , 5, e29	35.1	9
88	Manifold Learning of COPD. Lecture Notes in Computer Science, 2017, 586-593	0.9	1
87	Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	89
86	One-off Spirometry Is Insufficient to Rule In or Rule Out Mild to Moderate Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2017 , 196, 254-256	10.2	
85	Correlates and assessment of excess cardiovascular risk in bronchiectasis. <i>European Respiratory Journal</i> , 2017 , 50,	13.6	17
84	Effect of time and day of admission on hospital care quality for patients with chronic obstructive pulmonary disease exacerbation in England and Wales: single cohort study. <i>BMJ Open</i> , 2017 , 7, e015532	23	4
83	Deficiency Mutations of Alpha-1 Antitrypsin. Effects on Folding, Function, and Polymerization. <i>American Journal of Respiratory Cell and Molecular Biology</i> , 2016 , 54, 71-80	5.7	25
82	The use of whole-exome sequencing to disentangle complex phenotypes. <i>European Journal of Human Genetics</i> , 2016 , 24, 298-301	5.3	14
81	Differences in systemic adaptive immunity contribute to the 'frequent exacerbator' COPD phenotype. <i>Respiratory Research</i> , 2016 , 17, 140	7.3	15
80	Precision Medicine in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2016 , 193, 593-4	10.2	6
79	Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study. <i>European Respiratory Journal</i> , 2016 , 47, 186-93	13.6	275

(2014-2016)

78	Validation of the Recording of Acute Exacerbations of COPD in UK Primary Care Electronic Healthcare Records. <i>PLoS ONE</i> , 2016 , 11, e0151357	3.7	83
77	Monitoring of Physiological Parameters to Predict Exacerbations of Chronic Obstructive Pulmonary Disease (COPD): A Systematic Review. <i>Journal of Clinical Medicine</i> , 2016 , 5,	5.1	36
76	Recording of hospitalizations for acute exacerbations of COPD in UK electronic health care records. <i>Clinical Epidemiology</i> , 2016 , 8, 771-782	5.9	39
75	Update on alpha-1 antitrypsin deficiency: New therapies. <i>Journal of Hepatology</i> , 2016 , 65, 413-24	13.4	52
74	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. <i>Medicine</i> , 2016 , 44, 305-309	0.6	
73	Lung function, symptoms and inflammation during exacerbations of non-cystic fibrosis bronchiectasis: a prospective observational cohort study. <i>Respiratory Research</i> , 2015 , 16, 16	7.3	45
72	Lung consequences in adults born prematurely. <i>Thorax</i> , 2015 , 70, 574-80	7.3	7 ²
71	Lung disease in primary antibody deficiency. Lancet Respiratory Medicine, the, 2015, 3, 651-60	35.1	59
70	Hospitalized exacerbations of COPD: risk factors and outcomes in the ECLIPSE cohort. <i>Chest</i> , 2015 , 147, 999-1007	5.3	204
69	An Official American Thoracic Society/European Respiratory Society Statement: Research questions in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2015 , 191, e4-e27	10.2	137
68	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Journal</i> , 2015 , 45, 879-905	13.6	107
67	Effects of different antibiotic classes on airway bacteria in stable COPD using culture and molecular techniques: a randomised controlled trial. <i>Thorax</i> , 2015 , 70, 930-8	7.3	45
66	Associations between gastro-oesophageal reflux, its management and exacerbations of chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2015 , 109, 1147-54	4.6	31
65	Role of a functional polymorphism in the F2R gene promoter in sarcoidosis. <i>Respirology</i> , 2015 , 20, 1285	5-73.6	4
64	An official American Thoracic Society/European Respiratory Society statement: research questions in COPD. <i>European Respiratory Review</i> , 2015 , 24, 159-72	9.8	50
63	Lung consequences in adults born prematurely. <i>Postgraduate Medical Journal</i> , 2015 , 91, 712-8	2	10
62	Activity, severity and impact of respiratory disease in primary antibody deficiency syndromes. <i>Journal of Clinical Immunology</i> , 2014 , 34, 68-75	5.7	30
61	Impact of a functional polymorphism in the PAR-1 gene promoter in COPD and COPD exacerbations. <i>American Journal of Physiology - Lung Cellular and Molecular Physiology</i> , 2014 , 307, L311-	-6 ^{5.8}	8

60	Neither anti-inflammatory nor antibiotic treatment significantly shortens duration of cough in acute bronchitis compared with placebo. <i>Evidence-Based Medicine</i> , 2014 , 19, 98		1
59	Validation of chronic obstructive pulmonary disease recording in the Clinical Practice Research Datalink (CPRD-GOLD). <i>BMJ Open</i> , 2014 , 4, e005540	3	148
58	Microbial dysbiosis in bronchiectasis. Lancet Respiratory Medicine, the, 2014, 2, 945-7	35.1	8
57	Multi-scale analysis of imaging features and its use in the study of COPD exacerbation susceptible phenotypes. <i>Lecture Notes in Computer Science</i> , 2014 , 17, 417-24	0.9	2
56	COPD exacerbations: causes, prevention, and treatment. <i>Immunology and Allergy Clinics of North America</i> , 2013 , 33, 95-115	3.3	33
55	Factors associated with change in exacerbation frequency in COPD. Respiratory Research, 2013, 14, 79	7-3	47
54	Cardiovascular risk, myocardial injury, and exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2013 , 188, 1091-9	10.2	107
53	Chronic obstructive pulmonary disease: aetiology, pathology, physiology and outcome. <i>Medicine</i> , 2012 , 40, 257-261	0.6	O
52	COPD exacerbations: causes, prevention, and treatment. <i>Medical Clinics of North America</i> , 2012 , 96, 789	9- 8 09	27
51	Management of Exacerbations in Chronic Obstructive Pulmonary Disease 2012 , 562-567		
50	The impact of ischemic heart disease on symptoms, health status, and exacerbations in patients with COPD. <i>Chest</i> , 2012 , 141, 851-857	5.3	69
49	25-hydroxyvitamin D deficiency, exacerbation frequency and human rhinovirus exacerbations in chronic obstructive pulmonary disease. <i>BMC Pulmonary Medicine</i> , 2012 , 12, 28	3.5	41
48	Time course and pattern of COPD exacerbation onset. <i>Thorax</i> , 2012 , 67, 238-43	7.3	100
47	Usefulness of the Chronic Obstructive Pulmonary Disease Assessment Test to evaluate severity of COPD exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2012 , 185, 1218-24	10.2	144
46	Dose response of continuous positive airway pressure on nasal symptoms, obstruction and inflammation in vivo and in vitro. <i>European Respiratory Journal</i> , 2012 , 40, 1180-90	13.6	14
45	Detrended fluctuation analysis of peak expiratory flow and exacerbation frequency in COPD. <i>European Respiratory Journal</i> , 2012 , 40, 1123-9	13.6	18
44	Are early life factors considered when managing respiratory disease? A British Thoracic Society survey of current practice. <i>Thorax</i> , 2012 , 67, 1110	7.3	28
43	Intersession repeatability of a novel nasal lavage technique. <i>Translational Research</i> , 2011 , 158, 163-8	11	2

42	SERPINA1 11478G-A variant, serum 4-antitrypsin, exacerbation frequency and FEV1 decline in COPD. <i>Thorax</i> , 2011 , 66, 418-24	7.3	7
41	Extrapulmonary comorbidities in chronic obstructive pulmonary disease: state of the art. <i>Expert Review of Respiratory Medicine</i> , 2011 , 5, 647-62	3.8	100
40	The potential value of biomarkers in diagnosis and staging of COPD and exacerbations. <i>Seminars in Respiratory and Critical Care Medicine</i> , 2010 , 31, 267-75	3.9	18
39	Increased risk of myocardial infarction and stroke following exacerbation of COPD. <i>Chest</i> , 2010 , 137, 1091-7	5.3	275
38	Susceptibility to exacerbation in chronic obstructive pulmonary disease. <i>New England Journal of Medicine</i> , 2010 , 363, 1128-38	59.2	1840
37	The rhythm of chronic obstructive pulmonary disease exacerbations. <i>Journal of Clinical Epidemiology</i> , 2010 , 63, 1285-6	5.7	4
36	Temporal Clustering of Exacerbations in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2010 , 182, 985-985	10.2	1
35	Serum IP-10 as a biomarker of human rhinovirus infection at exacerbation of COPD. <i>Chest</i> , 2010 , 137, 812-22	5.3	88
34	Use and utility of a 24-hour Telephone Support Service for 'high risk' patients with COPD. <i>Primary Care Respiratory Journal: Journal of the General Practice Airways Group</i> , 2010 , 19, 260-5		13
33	Domiciliary pulse-oximetry at exacerbation of chronic obstructive pulmonary disease: prospective pilot study. <i>BMC Pulmonary Medicine</i> , 2010 , 10, 52	3.5	52
32	Temporal clustering of exacerbations in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 179, 369-74	10.2	187
31	Management and prevention of chronic obstructive pulmonary disease exacerbations: a state of the art review. <i>BMC Medicine</i> , 2009 , 7, 40	11.4	39
30	Determinants and impact of fatigue in patients with chronic obstructive pulmonary disease. <i>Respiratory Medicine</i> , 2009 , 103, 216-23	4.6	92
29	An introduction to conducting COPD exacerbation research. <i>Respiratory Medicine: COPD Update</i> , 2009 , 5, 38-44		
28	Temporal Clustering of COPD Exacerbations May Reflect Corticosteroid Withdrawal. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 483-483	10.2	
27	Frequent Exacerbators in COPD: Who Are They?. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2009 , 180, 284-284	10.2	
26	Exacerbation rate, health status and mortality in COPDa review of potential interventions. <i>International Journal of COPD</i> , 2009 , 4, 203-23	3	126
25	Long-term erythromycin therapy is associated with decreased chronic obstructive pulmonary disease exacerbations. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2008 , 178, 1139-47	10.2	314

24 Management of Acute Exacerbations of Chronic Obstructive Pulmonary Disease 2008, 517-521

23	The biology of a chronic obstructive pulmonary disease exacerbation. <i>Clinics in Chest Medicine</i> , 2007 , 28, 525-36, v	5.3	25
22	Structural and functional co-conspirators in chronic obstructive pulmonary disease exacerbations. <i>Proceedings of the American Thoracic Society</i> , 2007 , 4, 602-5		16
21	Changes to letters in Thorax. <i>Thorax</i> , 2007 , 62, 474-474	7.3	78
20	Mechanism of statin-associated mortality reduction in COPD. <i>Chest</i> , 2007 , 132, 1409; author reply 1409	9-503	7
19	Systemic and upper and lower airway inflammation at exacerbation of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 173, 71-8	10.2	261
18	Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2006 , 174, 867-74	10.2	329
17	Effect of interactions between lower airway bacterial and rhinoviral infection in exacerbations of COPD. <i>Chest</i> , 2006 , 129, 317-324	5.3	233
16	Nasal symptoms, airway obstruction and disease severity in chronic obstructive pulmonary disease. <i>Clinical Physiology and Functional Imaging</i> , 2006 , 26, 251-6	2.4	22
15	Airway and systemic inflammation and decline in lung function in patients with COPD. <i>Chest</i> , 2005 , 128, 1995-2004	5.3	336
14	Early Therapy in Chronic Obstructive Pulmonary Disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 292-292	10.2	
13	Exacerbations and time spent outdoors in chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2005 , 171, 446-52	10.2	220
12	Relationships among bacteria, upper airway, lower airway, and systemic inflammation in COPD. <i>Chest</i> , 2005 , 127, 1219-26	5.3	90
11	Early therapy improves outcomes of exacerbations of chronic obstructive pulmonary disease. <i>American Journal of Respiratory and Critical Care Medicine</i> , 2004 , 169, 1298-303	10.2	47 ⁰
10	Upper airway symptoms and quality of life in chronic obstructive pulmonary disease (COPD). <i>Respiratory Medicine</i> , 2004 , 98, 767-70	4.6	55
9	Prevalence, Severity and Mortality associated with COPD and Smoking in patients with COVID-19: A Rapid Systematic Review and Meta-Analysis		10
8	The nose and sinuses in COPD138-147		1
7	COPD: definition, severity and impact of pulmonary exacerbations13-24		

LIST OF PUBLICATIONS

6 Primary immunodeficiency153-166

5	Patient pathway modelling using discrete event simulation to improve the management of COPD. Journal of the Operational Research Society,1-25	1
4	The British Thoracic Society survey of rehabilitation to support recovery of the Post Covid-19 population	2
3	Long-Term Acceptability of Hygiene, Face Covering, and Social Distancing Interventions to Prevent Exacerbations in people living with Airways Diseases	2
2	Reduction in COPD exacerbations during COVID-19: a systematic review and meta-analysis	2
1	CONQUEST: A Quality Improvement Program for Defining and Optimizing Standards of Care for Modifiable High-Risk COPD Patients. <i>Patient Related Outcome Measures</i> , Volume 13, 53-68	О